WALTHAM, Mass., April 3, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today announced the pricing of the sale of 6,452,000 shares of its common stock in an underwritten public offering at a price to the public of $1.55 per share. The net offering proceeds to BG Medicine from the sale of the shares are expected to be approximately $8.9 million, after deducting underwriting discounts and commissions and other estimated offering expenses, but excluding any exercise of the underwriter’s over-allotment option.
Help employers find you! Check out all the jobs and post your resume.
